How a Blood Test May Help Guide Breast Cancer Treatment
Dr. Rita Mukhtar sits down for a conversation with Dr. Joshua Sabari to discuss the potential use of ctDNA to guide breast cancer therapy.
Read More
What Should Patients with Multiple Myeloma Know After ASCO 2025?
Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting.
Experts Impart Notable Information and Updates for Those With Blood Cancers
The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.
Advancements Reshape Treatment for Non-Small Cell Lung Cancer
Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the REZILIENT-1 and NeoADAURA trials.
Breaking Down the Impact of SERENA-6 for Some With Breast Cancer
Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.
Why is Clinical Trial Enrollment Important for Those With Kidney Cancer?
Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.
The Person Behind Their Diagnosis: Understanding the Patient
Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.
ctDNA-Guided Therapy May Improve Breast Cancer Outcomes
For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.
New Treatment Options Emerging Across Lung Cancer Subtypes
Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, according to experts.
Understanding the Whole Person Behind their Cancer Diagnosis
Dr. Joshua K. Sabari and Jackie Herigodt sat down to discuss the importance of knowing a patient beyond their cancer diagnosis.
Rybrevant Combo Improves Lung Cancer Outcomes After Tagrisso Failure
Rybrevant plus chemotherapy improved response and delayed disease progression for patients with EGFR-mutated non–small cell lung cancer after Tagrisso.
Explaining Brain Cancer and Metastases Updates for Patients
The 2025 ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.
Delving Into Brain Cancer Treatment Takeaways Following ASCO 2025
The de-escalation of therapy helps avoid unnecessary toxicity from treatment in patients with brain cancer, explained Drs. Joshua K. Sabari and Manmeet Singh Ahluwalia.
Breaking Down the VERIFY Trial for Patients With Polycythemia Vera
Dr. Aaron Gerds breaks down the outcomes of the phase 3 VERIFY trial, investigating rusfertide, for patients with polycythemia vera, a type of blood cancer.
Updates in Shared Decision-Making in Lung Cancer Following ASCO 2025
Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert oncologists.
What Should Patients With Lung Cancer Know After ASCO 2025?
Dr. Joshua K. Sabari and Dr. Prantesh Jain delve into key lung cancer outcomes from the 2025 ASCO Meeting that patients should be aware of.
Bringing Light to More Personalized Medicine in Lung Cancer After ASCO 2025
Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.
What Patients With Genitourinary Cancers Need to Know After ASCO 2025
Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.
What Patients With Genitourinary Cancers Should Know After ASCO 2025
Dr. Joshua K. Sabari sat down with Dr. Daniel V. Araujo to discuss topline takeaways from the 2025 ASCO Meeting across the realm of genitourinary oncology
Rusfertide Reduces Phlebotomy Need, Improves Quality of Life in Polycythemia Vera
Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.
Zilovertamab Vedotin Plus Chemo Combo Shows Responses in R/R DLBCL
The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.
Targeted Chemo Improves Survival in Early-Stage Lung Cancer
Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous lung cancer.
KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety
The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or refractory B-cell lymphoma.
Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation
Adding Zyprexa to ondansetron cut nausea and vomiting safely in abdominal/pelvic radiation with low-emetogenic capecitabine.
Sasanlimab-BCG Combo May Delay Recurrence in Bladder Cancer
Adding subcutaneous sasanlimab to BCG improved recurrence-free survival in non–muscle-invasive bladder cancer, according to Dr. Petros Grivas.
Columvi Combo Enhances Survival Outcomes in R/R Lymphoma Subgroup
Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nubeqa Combo Positively Impacts HRQoL vs Placebo in Prostate Cancer Subgroup
Nubeqa and ADT treatment led to positive impacts on health-related quality of life vs placebo in metastatic hormone-sensitive prostate cancer.
Rina-S Yields 50% Response Rate in Advanced Endometrial Cancer
Rina-S led to a 50% response rate, including two complete responses, in heavily pretreated advanced endometrial cancer, according to early trial findings.
Imdelltra Shows Survival Benefit in Small Cell Lung Cancer
Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, reinforcing it as a new SOC.
Targeting ESR1 Mutations Early May Improve Outcomes in Breast Cancer
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
